Lung Cancer Trials Ask AI to find trials
Active Not RecruitingNot applicableNCT02630615
Official study title

Circulating Tumor Cells (CTC) in Lung Cancer

Study summary

The primary objective of this study is to establish circulating tumor cell (CTC) derived xenografts and assess the activity of novel DNA repair inhibitors as a function of DNA repair mutations detected in CTC samples (personalize DNA repair therapy).

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBlood draw

The study team can explain what participation involves.

Who it may be forLung Neoplasms

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 24, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Observational

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?Shadia Jalal

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Shadia Jalal
Interventions being studied
Other: Blood draw
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Cohort A (one-time blood sample) \& Cohort B (multiple blood samples)
  • Histologically or cytologically confirmed lung cancer (both non-small cell lung cancer and small cell lung cancer are allowed)
  • Stage 4 NSCLC or extensive-stage SCLC
  • Newly diagnosed disease with no prior systemic therapy for advanced disease Note: Patients that have received prior adjuvant chemotherapy or prior chemoradiotherapy for earlier stage lung cancer are allowed if treatment was completed ≥3 months.
  • Age ≥ 18 years
  • Ability to understand and the willingness to sign a written informed consent document Inclusion of Women and Minorities Both men and women of all races and ethnic groups are eligible for this study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Indiana University Health Melvin and Bren Simon Cancer CenterIndianapolis, Indiana
  • Roudebush VA Medical CenterIndianapolis, Indiana

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 24, 2026. Always confirm current availability with the study team.

View original record ↗